Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.33 USD | -0.13% | +0.43% | +510.11% |
May. 09 | Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 02 | North American Morning Briefing : Stocks Seen -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 69.8M |
---|---|---|---|---|---|
Net income 2024 * | -26M | Net income 2025 * | -46M | EV / Sales 2024 * | - |
Net cash position 2024 * | 72.5M | Net cash position 2025 * | 30M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-9.5
x | P/E ratio 2025 * |
-13.3
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.54% |
1 day | -0.13% | ||
1 week | +0.43% | ||
Current month | +0.13% | ||
1 month | +3.81% | ||
3 months | +331.08% | ||
6 months | +525.49% | ||
Current year | +510.11% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Oakes
CEO | Chief Executive Officer | 56 | 22-06-20 |
Claudia Lopez
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Dawn Louro
CTO | Chief Tech/Sci/R&D Officer | - | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 57 | 17-08-31 | |
Tim Mayleben
BRD | Director/Board Member | 63 | 21-05-12 |
Alka Batycky
BRD | Director/Board Member | 54 | 23-05-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 22.33 | -0.13% | 10,749 |
24-05-09 | 22.36 | +0.70% | 5,058 |
24-05-08 | 22.2 | +0.16% | 5,249 |
24-05-07 | 22.17 | +0.09% | 7,834 |
24-05-06 | 22.15 | -0.38% | 6,357 |
Delayed Quote Nasdaq, May 10, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+510.11% | 69.8M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- LABP Stock